C. Négrier

发表

Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study

K. Baumstarck, P. Auquier, T. Lambert, 2018, BMJ Open.

Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.

C. Hermans, E. Santagostino, C. Kessler, 2019, Blood reviews.

Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) - advancing the journey.

C. Négrier, 2016, Thrombosis research.

Spotlight on the human factor: building a foundation for the future of haemophilia A management

J. Oldenburg, K. Khair, C. Kessler, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients

C. Négrier, A. Shapiro, M. Tarantino, 2008, Thrombosis and Haemostasis.

Haemophilia therapies

C. Négrier, Y. Dargaud, 2007, Expert opinion on biological therapy.

Incidence of Factor VIII Inhibitor Development in Severe Hemophilia A Patients Treated only with One Brand of Highly Purified Plasma-Derived Concentrate

C. Rothschild, M. Bertrand, C. Négrier, 1995, Thrombosis and Haemostasis.

Skewed X-chromosome inactivation in monochorionic diamniotic twin sisters results in severe and mild hemophilia A.

C. Négrier, M. Delpech, J. Lavergne, 2002, Blood.

Access to treatment among persons with hemophilia: A spatial analysis assessment in the Rhone-Alpes region, France.

C. Négrier, K. Tazarourte, F. Renard, 2019, Journal of the American Pharmacists Association : JAPhA.

Molecular cytogenetic characterization of five F8 complex rearrangements: utility for haemophilia A genetic counselling

C. Négrier, H. Chambost, S. Claeyssens-Donadel, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study

C. Négrier, D. Hart, R. Sidonio, 2021, Orphanet Journal of Rare Diseases.

Dose tailoring of human cell line‐derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A

E. Ollier, C. Négrier, Y. Dargaud, 2019, British journal of clinical pharmacology.

Haemophilia and thrombophilia: an unexpected association!

S. Meunier, C. Négrier, Y. Dargaud, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

The Treatment of Bleeding in Hemophilic Patients with Inhibitors with Recombinant Factor VIIa

C. Négrier, C. Hay, 2000, Seminars in thrombosis and hemostasis.

Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).

J. Oldenburg, A. Chuansumrit, E. Santagostino, 2016, Thrombosis research.

Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.

C. Négrier, Y. Dargaud, E. Perot, 2015, Thrombosis research.

The central role of thrombin in bleeding disorders.

C. Négrier, M. Shima, M. Hoffman, 2019, Blood reviews.

Protein S: A multifunctional anticoagulant vitamin K-dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer.

Claude Négrier, C. Négrier, Lutfi Suleiman, 2013, Critical reviews in oncology/hematology.

Protein S-mediated signal transduction pathway regulates lung cancer cell proliferation, migration and angiogensis

C. Négrier, H. Boukerche, Lutfi Suleiman, 2021, Hematology/Oncology and Stem Cell Therapy.

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A

C. Négrier, C. Solomon, R. Klamroth, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX

C. Négrier, Y. Dargaud, E. Perot, 2018, Thrombosis and Haemostasis.

Pre-analytical effects of pneumatic tube system transport on routine haematology and coagulation tests, global coagulation assays and platelet function assays.

C. Négrier, Y. Dargaud, J. Bordet, 2017, Thrombosis research.

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia

S. Milstein, K. G. Rajeev, M. Manoharan, 2015, Nature Medicine.

Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements

A. Lienhart, S. Meunier, C. Négrier, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels

C. Négrier, Y. Dargaud, D. Monroe, 2013, Journal of thrombosis and haemostasis : JTH.

Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study.

T. Baglin, C. Négrier, H. ten Cate, 2012, Thrombosis research.

Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots

A. Lienhart, C. Négrier, Y. Dargaud, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Standardisation of thrombin generation test--which reference plasma for TGT? An international multicentre study.

T. Baglin, C. Négrier, T. Lecompte, 2010, Thrombosis research.

Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery.

A. Lienhart, C. Négrier, Y. Dargaud, 2010, Blood.

Thrombin generation in patients with factor XI deficiency and clinical bleeding risk

P. de Mazancourt, C. Négrier, Y. Dargaud, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Thrombin generation testing in haemophilia comprehensive care centres

C. Négrier, Y. Dargaud, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.

C. Négrier, Y. Dargaud, H. Desmurs-Clavel, 2009, Thrombosis research.

Intraindividual thrombin generation measurement variability in healthy adults over a one year period.

C. Négrier, Y. Dargaud, Stéphanie Francillon, 2009, Thrombosis research.

Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study

C. Négrier, Y. Dargaud, J. Bordet, 2008, Journal of thrombosis and haemostasis : JTH.

Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study

T. Baglin, C. Négrier, T. Lecompte, 2007, British journal of haematology.

Thrombin-generating capacity in patients with von Willebrand’s disease

S. Béguin, C. Négrier, Y. Dargaud, 2007, Haematologica.

Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision

A. Lienhart, S. Meunier, C. Négrier, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor VIII Inhibitor-Bypassing Agents Act by Inducing Thrombin Generation and Can Be Monitored by a Thrombin Generation Assay

J. Astermark, M. Morfini, C. Négrier, 2003, Pathophysiology of Haemostasis and Thrombosis.

The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors

A. al‐Sabbagh, C. Hermans, C. Leissinger, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Analytic variability due to change of deficient plasma vials: application to one-stage clotting factor VIII assay

A. Lienhart, C. Négrier, T. K. Nguyen, 2011, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Bayesian logic in statistical test control: application to coagulation factor VIII assay

P. Tsiamyrtzis, A. Lienhart, C. Négrier, 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Use of calibrated automated thrombinography ± thrombomodulin to recognise the prothrombotic phenotype

C. Négrier, Y. Dargaud, J. Ninet, 2006, Thrombosis and Haemostasis.

Spectrum of the Mutations in Bernard–Soulier Syndrome

A. Pastore, P. Noris, R. Favier, 2014, Human mutation.

Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency

C. Négrier, Y. Dargaud, H. Boukerche, 2010, Journal of thrombosis and haemostasis : JTH.

Monitoring the bioavailability of FEIBA with a thrombin generation assay

J. Astermark, M. Morfini, C. Négrier, 2003, Journal of thrombosis and haemostasis : JTH.

The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study

C. Négrier, C. Hay, C. Ludlam, 1997, Thrombosis and Haemostasis.

A case of Glanzmann's thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug.

C. Négrier, Y. Dargaud, C. Vinciguerra, 2006, Haematologica.

Inherited bleeding disorder due to familial type 2 platelet cyclo-oxygenase deficiency.

C. Négrier, M. Dechavanne, Y. Dargaud, 2005, Thrombosis research.

Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey

M. Morfini, K. Khair, C. Négrier, 2004, Journal of thrombosis and haemostasis : JTH.

Global haemostasis and point of care testing

C. Négrier, M. Shima, A. Srivastava, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Postauthorization safety study of Clottafact®, a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study

T. Lambert, A. Borel‐Derlon, Y. Gruel, 2018, Vox sanguinis.

Factor XI and traveling waves: the key to understanding coagulation in hemophilia?

C. Négrier, F. Ataullakhanov, M. Panteleev, 2013, Expert review of hematology.

Splicing analysis of 26 F8 nucleotide variations using a minigene assay

D. Bozon, C. Négrier, C. Vinciguerra, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making

C. Goodman, F. Driessler, C. Négrier, 2022, Patient preference and adherence.

PPA_A_355627 1439..1447

C. Goodman, F. Driessler, C. Négrier, 2022 .

Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)

E. Santagostino, C. Négrier, R. Klamroth, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics of a novel extended half‐life glycoPEGylated factor IX, nonacog beta pegol (N9‐GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials

J. Oldenburg, E. Santagostino, M. Carcao, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant long‐acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials

C. Négrier, G. Young, P. Collins, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)

P. Giangrande, J. Goudemand, C. Négrier, 2011, Journal of thrombosis and haemostasis : JTH.

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.

P. Giangrande, C. Négrier, A. Tiede, 2011, Blood.

Determining the adequate number of internal quality control levels: the example of coagulation factor VIII assay

L. Mazliak, A. Lienhart, C. Négrier, 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Hemophilia Care in the New Millennium

C. Négrier, G. White, D. Monroe, 2001, Advances in Experimental Medicine and Biology.

Factor VIII recovery after a single infusion of recalibrated ReFacto® in 14 severe haemophilia A patients

T. Lambert, M. Bertrand, V. Gay, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Two novel mutations in EGF‐like domains of human factor IX dramatically impair intracellular processing and secretion

C. Négrier, C. Vinciguerra, N. Enjolras, 2004, Journal of thrombosis and haemostasis : JTH.

Hypofibrinolytic state and high thrombin generation may play a major role in SARS‐COV2 associated thrombosis

L. Argaud, C. Négrier, M. Simon, 2020, Journal of Thrombosis and Haemostasis.

Coagulation factor concentrates: past, present, and future

C. Négrier, N. Key, 2007, The Lancet.

Experiences with continuous infusion of recombinant activated factor VII.

M. Morfini, J. Goudemand, C. Négrier, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Patients’ Perception of the Impact of Innovation on Hemophilia Care Management Organization: A Qualitative Study Protocol (INNOVHEMO Study)

V. Gay, C. Négrier, V. Chamouard, 2021, Patient preference and adherence.

Single‐center determination of reference factor II and factor X activity level values for the monitoring of vitamin K antagonist therapy

C. Négrier, Y. Jourdy, S. Le Quellec, 2019, International journal of laboratory hematology.

Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study

S. Susen, A. Harroche, A. Borel‐Derlon, 2020, Journal of thrombosis and haemostasis : JTH.

Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?

C. Négrier, Y. Dargaud, C. Vinciguerra, 2017, PloS one.

Effect of five therapeutic strategies on the coagulation defect induced by the thrombomodulin c.1611C>A mutation

C. Négrier, Y. Dargaud, C. Hemker, 2015, British journal of haematology.

Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation.

H. Hemker, J. Scoazec, C. Négrier, 2015, Blood.

Once‐weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9‐GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials

J. Oldenburg, M. Carcao, C. Négrier, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety update on the use of recombinant activated factor VII in approved indications.

E. Neufeld, P. Arkhammar, C. Négrier, 2015, Blood reviews.

Successive bleeding and thrombotic complications in a patient with afibrinogenemia: a case report.

L. Argaud, C. Négrier, Y. Dargaud, 2011, Thrombosis research.

Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial

C. Négrier, B. Konkle, D. Viuff, 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Haemophilia in France: Modelisation of the Clinical Pathway for Patients

V. Gay, C. Négrier, D. Bourgeois, 2022, International journal of environmental research and public health.

Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate

M. Alessi, C. Rothschild, J. Goudemand, 2008, Journal of thrombosis and haemostasis : JTH.

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference

J. Astermark, J. Oldenburg, C. Leissinger, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Two novel factor V null mutations associated with activated protein C resistance phenotype/genotype discrepancy

S. Meunier, C. Négrier, Dorothé Pellechia, 2003, British journal of haematology.

and VIII Deficiency Families ERGIC-53 Gene Structure and Mutation Analysis in 19 Combined Factors V

R. Kaufman, C. Négrier, H. Saito, 2013 .

ERGIC-53 gene structure and mutation analysis in 19 combined factors V and VIII deficiency families.

R. Kaufman, C. Négrier, D. Ginsburg, 1999, Blood.

Overall experience with NovoSeven®

A. Lienhart, C. Négrier, 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Use of Recombinant Factor VIIa in 3 Patients with Inherited Type I Glanzmann’s Thrombasthenia Undergoing Invasive Procedures

P. Nurden, C. Négrier, R. d'Oiron, 2000, Thrombosis and Haemostasis.

Multiple arterial thromboses in a patient with primary antiphospholipid syndrome receiving a bromocriptine therapy

C. Négrier, Y. Dargaud, J. Ninet, 2004, Lupus.

Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc

C. Négrier, S. Lethagen, E. Berntorp, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Evaluation of the impact of information about treatment‐related risks in patients receiving blood‐derived or recombinant medications

J. Goudemand, C. Négrier, N. Ounnoughene, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement

A. Iorio, E. Iserman, J. Oldenburg, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemophilia patients exhibit prolonged coagulation time but normal lag time of thrombin generation test: Are these results really discordant?

C. Négrier, Y. Dargaud, J. Bordet, 2007, Thrombosis and Haemostasis.

Successful treatment of acquired factor VIII antibody by extracorporeal immunoadsorption.

C. Négrier, F. Alfonsi, M. Dechavanne, 1991, Acta haematologica.

Effects of hemolysis, bilirubin, and lipemia interference on coagulation tests detected by two analytical systems

C. Négrier, C. Nougier, F. Sobas, 2019, International journal of laboratory hematology.

Impact of quality control matrix effect: application to the calculation of uncertainty of measurement in one-stage clotting factor VIII assay

A. Lienhart, C. Négrier, A. Bellisario, 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Utilization of Previously Treated Patients (PTPs), Noninfected Patients (NIPs), and Previously Untreated Patients (PUPs) in the Evaluation of New Factor VIII and Factor IX Concentrates

C. Prowse, C. Négrier, R. Schwaab, 1999, Thrombosis and Haemostasis.

Phase I study of interleukin-6 in children with solid tumours in relapse.

J. Blay, D. Frappaz, A. Gianella-Borradori, 1997, European journal of cancer.

A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study

C. Négrier, P. Gaucherand, Y. Dargaud, 2009, British journal of haematology.

Management of pregnant women with increased risk of venous thrombosis

C. Négrier, Y. Dargaud, J. Ninet, 2005, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

The potential role of synovial thrombomodulin in the pathophysiology of joint bleeds in haemophilia

O. Guyen, J. Scoazec, T. Baglin, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Increased thrombosis incidence in a family with an inherited protein S deficiency and a high oxygen affinity hemoglobin variant

C. Négrier, B. Boneu, M. Dechavanne, 1994, American journal of hematology.

Personalising haemophilia management with shared decision making

L. Valentino, V. Blanchette, C. Négrier, 2021, The Journal of Haemophilia Practice.

The use of porcine factor VIII in France.

C. Négrier, 1994, Seminars in hematology.

An unusual clinical presentation of factor XIII deficiency and issues relating to the monitoring of factor XIII replacement therapy

P. de Mazancourt, C. Négrier, P. Gaucherand, 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Human hepatoma cell line HuH-7 is an effective cellular system to produce recombinant factor IX with improved post-translational modifications.

C. Négrier, Y. Dargaud, M. Becchi, 2012, Thrombosis research.

Emicizumab should be prescribed independent of immune tolerance induction.

C. Négrier, S. Le Quellec, 2018, Blood advances.

Inhibitors to Factor VIII: Treatment of Acute Bleeds

C. Négrier, 2014 .

Effect of pre-analytical conditions on the thrombodynamics assay.

C. Négrier, F. Ataullakhanov, M. Panteleev, 2014, Thrombosis research.

Human herpesvirus 6 infection and transient acquired myelodysplasia in children

Y. Bertrand, C. Négrier, V. Mialou, 2006, Pediatric blood & cancer.

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia

L. Valentino, C. Négrier, P. Monahan, 2021, Journal of clinical medicine.

The pharmacokinetics of coagulation factors

M. Morfini, C. Négrier, M. Lee, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Prophylactic Dosing of Anti Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors Results of the Pro FEIBA Study

C. Leissinger, C. Négrier, E. Berntorp, 2010 .

Recombinant activated factor VII in approved indications: Update on safety

E. Neufeld, D. Cooper, C. Négrier, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII.

A. Lienhart, C. Négrier, Y. Dargaud, 2008, Seminars in hematology.

The concept of recombinant factor VIIa megadose for treating bleeding episodes in high‐titer inhibitor patients with hemophilia: toward an expanding indication?

C. Négrier, 2003, Journal of thrombosis and haemostasis : JTH.

Treatment of interleukin-2-induced thrombocytopenia by intravenous immunoglobulin.

V. Cottin, C. Négrier, T. Philip, 1994, European journal of cancer.

Gene therapy for hemophilia? Yes

C. Négrier, 2004, Journal of thrombosis and haemostasis : JTH.

Switching patients in the age of long-acting recombinant products?

A. Iorio, E. Santagostino, C. Négrier, 2019, Expert review of hematology.

Illegitimate transcription: its use for studying genetic abnormalities in lymphoblastoid cells from patients with Glanzmann thrombasthenia

C. Négrier, M. Dechavanne, C. Vinciguerra, 1998, British journal of haematology.

Molecular Study of Glanzmann Thrombasthenia in 3 Patients Issued from 2 Different Families

D. Frappaz, C. Négrier, M. Dechavanne, 1995, Thrombosis and Haemostasis.

The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor

C. Négrier, E. Gomperts, J. Oldenburg, 2006 .

Expanding the Mutation Spectrum Affecting αIIbβ3 Integrin in Glanzmann Thrombasthenia: Screening of the ITGA2B and ITGB3 Genes in a Large International Cohort

L. Alberio, R. Heilig, A. Couloux, 2015, Human mutation.

Human plasma fibrinogen measurement derived from activated partial thromboplastin time clot formation

C. Négrier, M. Dechavanne, M. Hanss, 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Increased thrombin generation in a child with a combined factor IX and protein C deficiency.

C. Négrier, M. Dechavanne, A. Durin, 1993, Blood.

Impaired factor XIII activation in patients with congenital afibrinogenemia

C. Négrier, A. Casini, P. de Moerloose, 2018, Haematologica.

Use of Haemate® P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study

C. Rothschild, A. Borel‐Derlon, Y. Gruel, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors

C. Rothschild, M. Bertrand, J. Goudemand, 1997, Thrombosis and Haemostasis.

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

C. Négrier, G. Young, M. Callaghan, 2020, Thrombosis and Haemostasis.

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors

C. Négrier, S. Meeks, G. Kenet, 2022, Research and practice in thrombosis and haemostasis.

The application of bypassing‐agent prophylaxis in haemophilia A patients with inhibitors: a meeting report

L. Valentino, C. Leissinger, V. Blanchette, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Endogenous thrombin potential, prothrombin fragment 1+2 and D-dimers during pregnancy

C. Négrier, P. Gaucherand, Y. Dargaud, 2009, Thrombosis and Haemostasis.

Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors

J. Oldenburg, C. Négrier, W. Schramm, 2020, Hämostaseologie.

Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors

C. Hermans, Michael Wang, M. Carcao, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies.

J. Oldenburg, V. Jiménez‐Yuste, S. Chebon, 2020, Blood.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

J. Oldenburg, V. Jiménez‐Yuste, C. Kempton, 2018, The New England journal of medicine.

Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method

G. Spotts, V. Blanchette, C. Négrier, 2004 .

Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK.

G. Spotts, V. Blanchette, C. Négrier, 2004, Seminars in hematology.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

J. Oldenburg, E. Santagostino, C. Kessler, 2017, The New England journal of medicine.

Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate)

C. Négrier, F. Baghaei, A. Gringeri, 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

FEIBA in the treatment of acquired haemophilia A: Results from the prospective multicentre French ‘FEIBA dans l'hémophilie A acquise’ (FEIBHAC) registry

I. Durieu, C. Négrier, H. Lévesque, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies

A. Lienhart, C. Négrier, F. Baghaei, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

A retrospective postlicensure survey of FEIBA efficacy and safety

C. Négrier, D. DiMichele, D. DiMichele, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates

M. Ozelo, C. Négrier, A. Shapiro, 2015, British journal of haematology.

The association of haemophilic arthropathy with Health‐Related Quality of Life: a post hoc analysis

C. Négrier, K. Fischer, R. Schutgens, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Achievements, challenges and unmet needs for haemophilia patients with inhibitors

D. Scott, David Steven Scott, S. Lacroix-Desmazes, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcome

D. Grobbee, C. Négrier, K. Fischer, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Evaluation of early musculoskeletal disease in patients with haemophilia: results from an expert consensus

C. Négrier, C. Djambas Khayat, A. Seuser, 2018, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Successful arthroscopic synovectomy using holmium: Yag laser and feiba in a high responder hemophiliac

C. Négrier, M. Dechavanne, J. J. Lalain, 1993, American journal of hematology.

Unresolved issues in prophylaxis

J. Astermark, C. Leissinger, V. Blanchette, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

A comparison of the 12s rule and Bayesian approach for quality control: application to one-stage clotting factor VIII assay

Panagiotis Tsiamyrtzis, Frédéric Sobas, Claude Négrier, 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Seventy‐two total knee arthroplasties performed in patients with haemophilia using continuous infusion

A. Lienhart, C. Négrier, Y. Dargaud, 2013, Vox sanguinis.

In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH‐7

C. Négrier, Y. Dargaud, E. Perot, 2015, Haemophilia.

C. Leissinger, M. Morfini, C. Négrier, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

M. Morfini, E. Santagostino, C. Négrier, 2012, Blood.

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

B. Kerlin, C. Négrier, M. Mancuso, 2020, Thrombosis and Haemostasis.

Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders

B. Guillet, C. Négrier, J. Windyga, 2022, Thrombosis and haemostasis.

Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A.

K. Baumstarck, P. Moreau, T. Lambert, 2021, The Journal of pediatrics.

Consensus recommendations for the use of FEIBA® in haemophilia A patients with inhibitors undergoing elective orthopaedic and non‐orthopaedic surgery

C. Négrier, E. Rodríguez‐Merchán, N. Goddard, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives.

Guy Young, C. Négrier, N. Key, 2013, Blood.

Identifying non‐responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition

C. Négrier, G. Young, P. Collins, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Basic aspects of bypassing agents

C. Négrier, Y. Dargaud, J. Bordet, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement

J. Goudemand, C. Négrier, E. Rodríguez‐Merchán, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Spontaneous proximal deep vein thrombosis in a patient with severe haemophilia A.

A. Lienhart, C. Négrier, Y. Dargaud, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.

P. Cortesi, L. Mantovani, C. Leissinger, 2011, The New England journal of medicine.

Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B

H. Hemker, R. al Dieri, S. Béguin, 2005, Thrombosis and Haemostasis.

Optimizing on‐demand treatment with NovoSeven® room temperature stable

C. Négrier, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.

J. Oldenburg, C. Négrier, J. Mahlangu, 2014, Blood.

Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.

J. Oldenburg, C. Hermans, V. Jiménez‐Yuste, 2023, The Lancet. Haematology.

Haemophilic arthropathy from A to Z

T. Lambert, J. Goudemand, C. Négrier, 2008, Haemophilia.

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

J. Oldenburg, V. Jiménez‐Yuste, S. Chebon, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.

V. Blanchette, C. Rothschild, C. Négrier, 2005, Blood.

Continuous intravenous infusion of a plasma‐derived factor IX concentrate (Mononine®) in haemophilia B

C. Leissinger, C. Négrier, S. Schulman, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

E. Santagostino, L. Boggio, C. Négrier, 2016, Blood.

factor IX : a first human dose trial in patients with hemophilia B Enhanced pharmacokinetic properties of a glycoPEGylated recombinant

P. Giangrande, C. Négrier, A. Tiede, 2011 .

Title Page Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: A first human dose trial in patients with hemophilia B Running Title

P. Giangrande, C. Négrier, A. Tiede, 2017 .

A Cross-over Pharmacokinetic Study of a Double Viral Inactivated Factor IX Concentrate (15 nm Filtration and SD) Compared to a SD Factor IX Concentrate

J. Goudemand, C. Négrier, H. Chambost, 1998, Thrombosis and Haemostasis.

Efficacy and safety of long‐acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

E. Santagostino, A. Lienhart, C. Négrier, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study

J. Oldenburg, E. Santagostino, C. Kessler, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

C. Négrier, P. Holme, I. Pabinger, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

A Factor VIII Minigene Comprising the Truncated Intron I of Factor IX Highly Improves the In Vitro Production of Factor VIII

C. Négrier, N. Enjolras, J. Plantier, 2001, Thrombosis and Haemostasis.

An unusual haemarthrosis in an HIV‐seronegative haemophilia A patient

C. Négrier, M. Dechavanne, P. Duhaut, 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

First report on the safety and efficacy of an extended half‐life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A

E. Santagostino, A. Neff, C. Négrier, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

The benefits of exercise for patients with haemophilia and recommendations for safe and effective physical activity

Sébastien Lobet, A. Seuser, C. Négrier, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor VIII gene inversions in severe hemophilia A: results of an international consortium study.

F E Preston, P G Mori, S S Sommer, 1995, Blood.

New developments in laboratory diagnosis and monitoring

C. Négrier, S. Kitchen, Y. Dargaud, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor IX Gene Analysis In 70 Unrelated Patients with Haemophilia B: Description of 13 New Mutations

V. Gay, C. Négrier, M. Dechavanne, 1999, Thrombosis and Haemostasis.

A novel protocol for accurate and reliable postoperative bolus administration of recombinant factor VIIa using an automated mini‐pump system

A. Lienhart, C. Négrier, V. Chamouard, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

The first recombinant FVIII produced in human cells – an update on its clinical development programme

L. Valentino, C. Négrier, R. Liesner, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH HEMOPHILIA RECEIVING FITUSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC TARGETING ANTITHROMBIN FOR THE TREATMENT OF HEMOPHILIA

C. Négrier, K. Pasi, T. Lissitchkov, 2020 .

Combined hereditary disorders of haemophilia B Leyden (-6 G-->A) and type 1 von Willebrand disease.

C. Négrier, B. Polack, G. Pernod, 1996, Thrombosis and haemostasis.

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

C. Négrier, P. Holme, M. Mancuso, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH

H. Hemker, C. Négrier, A. Wolberg, 2017, Journal of thrombosis and haemostasis : JTH.

PHAREO study: Perceived and observed accessibility to therapeutic drugs used for treating patients with inherited bleeding disorders

C. Négrier, J. Freyssenge, V. Chamouard, 2022 .

A prospective, randomized, and crossover study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors (Pro-FEIBA): subject demographics and safety data

C. Leissinger, C. Négrier, E. Berntorp, 2010 .

Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP.

E. Santagostino, C. Négrier, W. Seifert, 2020, Thrombosis research.

Management of an anti-factor VIII inhibitor occurring during surgical procedure with continuous infusion of Novoseven.

C. Négrier, C. Menart, P. Petit, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Continuous infusion of B‐domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience

G. Auerswald, C. Négrier, S. Schulman, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of continuous infusion of Mononine® during five surgical procedures in three hemophilic patients

C. Négrier, M. Dechavanne, P. Petit, 1998, American journal of hematology.

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one‐stage clotting assays

C. Négrier, K. Friedman, W. Seifert, 2018, Journal of thrombosis and haemostasis : JTH.

Potential limits of AAV‐based gene therapy with the use of new transgenes expressing factor IX fusion proteins

C. Négrier, A. Dane, A. Nathwani, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Expression of Coagulation Factor IX in a Haematopoietic Cell Line

C. Négrier, M. Leboeuf, G. Uzan, 2002, Thrombosis and Haemostasis.

Stability and microbiological safety of clotting factor concentrates in CADD PRIZM VIP™ pump: a preliminary study

C. Négrier, V. Chamouard, S. Moreau, 2001 .

Characteristics of Bleed-Free Patients on Every-5-Day Dosing in the Protect VIII (BAY 94-9027) Study

B. Kerlin, E. Santagostino, C. Négrier, 2018, Blood.

Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)

E. Santagostino, F. Driessler, C. Négrier, 2018, Blood.

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study

J. Oldenburg, C. Négrier, J. Mahlangu, 2017 .

Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) for prophylaxis and treatment of bleeding episodes in patients with haemophilia B

J. Oldenburg, C. Négrier, J. Mahlangu, 2013 .

European curriculum for thrombosis and haemostasis

J. Astermark, C. Hermans, C. Négrier, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.

A. Lienhart, C. Négrier, M. Dechavanne, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute Bleeding Events

C. Négrier, S. Pipe, M. Ragni, 2019, Blood.

Laboratory Assays to Predict Response to Bypassing Agents

C. Négrier, B. Sørensen, 2011 .

Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice

C. Négrier, Y. Dargaud, F. Mingozzi, 2019, Thrombosis and Haemostasis.

Report of surgeries, their outcome and the thrombin generation assay in patients with Factor XI deficiency: A retrospective single‐centre study

A. Lienhart, S. Meunier, C. Négrier, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab

A. Lienhart, C. Négrier, Y. Dargaud, 2018, Haematologica.

Considerations in the management of patients with haemophilia and inhibitors

C. Négrier, E. Gomperts, 2006 .

Combined factor IX and protein C deficiency in a child: Thrombogenic effects of two factor IX concentrates

C. Négrier, M. Dechavanne, C. Vinciguerra, 1995, American journal of hematology.

Efficacy and safety of rIX-FP in surgery: An update from a phase 3b extension study.

A. Tosetto, C. Négrier, W. Seifert, 2020, Thrombosis research.

Clinical pharmacology, efficacy and safety study of a triple‐secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency

T. Lambert, V. Gay, C. Négrier, 2019, Journal of thrombosis and haemostasis : JTH.

Perioperative Management in Patients with Hemophilia Receiving Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

C. Négrier, K. Pasi, T. Lissitchkov, 2017 .

Management of intracranial haemorrhage in a newborn with inherited factor VII deficiency with the use of rFVIIa aliquots

S. Meunier, C. Négrier, V. Chamouard, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

PPA_A_322531 1807..1815

V. Gay, C. Négrier, V. Chamouard, 2021 .

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

J. Oldenburg, C. Hermans, V. Jiménez‐Yuste, 2021, Blood.

First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a

E. Santagostino, A. Neff, C. Négrier, 2015 .

Chromogenic analysis of FIX activity in haemophilia B patients treated with nonacog beta pegol

J. Oldenburg, C. Négrier, G. Young, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

REACH: A programme for improving care in haemophilia

C. Négrier, F. Alkasim, A. Khelif, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

J. Oldenburg, A. Chuansumrit, E. Santagostino, 2014 .

The P‐selectin cytoplasmic domain directs the cellular storage of a recombinant chimeric factor IX

C. Négrier, E. Cramer, J. Massé, 2003, Journal of thrombosis and haemostasis : JTH.

B-domain deleted factor VIII is aggregated and degraded through proteasomal and lysosomal pathways

B. Guillet, C. Négrier, V. Rolli, 2005, Thrombosis and Haemostasis.

Multiple criteria decision analysis for therapeutic innovations in a hemophilia care center: A pilot study of the organizational impact of innovation in hemophilia care management

V. Gay, C. Négrier, F. Carrouel, 2022, PloS one.

Characterization of five associations of F8 missense mutations containing FVIII B domain mutations

C. Négrier, C. Vinciguerra, O. Roualdes, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Usefulness of an in vitro cellular expression model for haemophilia A carrier diagnosis: illustration with five novel mutations in the F8 gene in women with isolated factor VIII:C deficiency

C. Négrier, C. Vinciguerra, O. Roualdes, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Biosynthesis of FVIII in megakaryocytic cells: improved production and biochemical characterization

C. Négrier, M. Leboeuf, G. Uzan, 2004, British journal of haematology.

Study of six patients with complete F9 deletion characterized by cytogenetic microarray: role of the SOX3 gene in intellectual disability

V. Gay, S. Meunier, C. Négrier, 2016, Journal of thrombosis and haemostasis : JTH.

Functional mapping of the A2 domain from human factor VIII

J. Pellequer, C. Négrier, M. Delcourt, 2012, Thrombosis and Haemostasis.

Functional mapping of factor VIII C2 domain

Shu‐wen W. Chen, J. Pellequer, C. Négrier, 2011, Thrombosis and Haemostasis.

MDA-9/Syntenin Is Essential for Factor VIIa-induced Signaling, Migration, and Metastasis in Melanoma Cells*

C. Négrier, J. Bordet, H. Boukerche, 2014, The Journal of Biological Chemistry.

Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography

B. Allaouchiche, B. Floccard, C. Négrier, 2007, Journal of thrombosis and haemostasis : JTH.

Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients.

K. Inaba, B. Floccard, C. Négrier, 2008, British journal of anaesthesia.

[Reference center for platelet diseases].

P. Nurden, R. Favier, C. Négrier, 2007, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

Description of 10 new mutations in platelet glycoprotein IIb (αIIb) and glycoprotein IIIa (β3) genes

C. Négrier, M. Dechavanne, C. Vinciguerra, 2001, Platelets.

Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF

C. Négrier, Y. Jourdy, L. Rugeri, 2018, International journal of laboratory hematology.

Alpha Cyano-4-Hydroxy-3-Methoxycinnamic Acid Inhibits Proliferation and Induces Apoptosis in Human Breast Cancer Cells

C. Négrier, H. Boukerche, Z. Arrar, 2013, PloS one.

Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.

M. Morfini, M. Torchet, C. Berger, 2001, Seminars in hematology.

Sequential Regulation of the Small GTPase Rap1 in Human Platelets

J. Bos, C. Négrier, J. Akkerman, 2000, Molecular and Cellular Biology.

Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women. A rebuttal.

C. Négrier, Y. Dargaud, J. Ninet, 2008, Thrombosis research.

ix recombinant factor production in a human hepatocyte cell line

C. Négrier, Y. Dargaud, N. Enjolras, 2009 .

Characterization of four novel molecular changes in the promoter region of the factor VIII gene

C. Négrier, C. Vinciguerra, O. Roualdes, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Early coagulopathy in trauma patients: an on-scene and hospital admission study.

B. Allaouchiche, B. Floccard, C. Négrier, 2012, Injury.

A nonsense mutation in the GPIIb heavy chain (Ser 870 → stop) impairs platelet GPIIb–IIIa expression

F. Morlé, C. Négrier, M. Dechavanne, 1996, British journal of haematology.

[Thrombosis of superior longitudinal sinus and pulmonary embolism in nephrotic syndrome].

B. Ranchin, R. Bouvier, C. Négrier, 1992, Pediatrie.

Early septic shock induces loss of oxidative phosphorylation yield plasticity in liver mitochondria

J. Viale, D. Roussel, C. Négrier, 2014, Journal of Physiology and Biochemistry.

IN VITRO TESTS FOR ASSESSING HEPARIN-INDUCED THROMBOCYTOPENIA IN PATIENTS AFTER ELECTIVE HIP REPLACEMENT

C. Négrier, M. Dechavanne, C. Colin, 2002, International Journal of Technology Assessment in Health Care.

Successful systemic thrombolysis of hepatic vein thrombosis in a patient with promyelocytic leukemia treated with all‐trans retinoic acid

E. Archimbaud, C. Négrier, D. Bodnar, 1995, American journal of hematology.

Hepatitis A in French Hemophiliacs

J. Fonlupt, J. Goudemand, C. Négrier, 1994, Vox sanguinis.

A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal

D. Galanaud, P. Coriat, Jeannot Schmidt, 2013, Critical Care.

Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response

C. Négrier, Y. Dargaud, J. Bordet, 2016, Thrombosis and Haemostasis.

Characterisation of 96 mutations in 128 unrelated severe haemophilia A patients from France

C. Berger, C. Négrier, C. Zawadzki, 2006, Thrombosis and Haemostasis.

Post‐authorization safety study of Clottafact®, a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study

T. Lambert, C. Rothschild, Y. Gruel, 2016, Vox sanguinis.

The highly prevalent deletions in F8 intron 13 found in French mild hemophilia A patients result from both founder effect and recurrent de novo events

C. Négrier, D. Lillicrap, C. Vinciguerra, 2018, Journal of thrombosis and haemostasis : JTH.

Contribution of genetical analysis for diagnosis of von Willebrand’s disease type 2B

S. Meunier, C. Négrier, C. Vinciguerra, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Coagulation dynamics of a blood sample by multiple scattering analysis.

P. Peltié, P. Pouteau, A. Planat-Chretien, 2011, Journal of biomedical optics.

Prospective evaluation of automatized PF4/heparin immunoassays HemosIL HIT‐ab (PF4‐H) for the diagnosis of heparin‐induced thrombocytopenia

C. Négrier, J. Bordet, Y. Jourdy, 2015, International journal of laboratory hematology.

development destroys a major FVIII antigenic determinant involved in inhibitor hemophilia A by impairing FVIII binding to VWF and phospholipids and Deletion of alanine 2201 in the FVIII C2 domain results in mild

J. Vermylen, C. Négrier, K. Peerlinck, 2013 .

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.

J. Vermylen, C. Négrier, K. Peerlinck, 2004, Blood.

ANALYSIS OF THE RISK OF TRANSMISSION OF VARIANT OF CREUTZFELDT-JAKOB DISEASE BY HEALTH PRODUCTS AND BY TISSUES AND FLUIDS OF HUMAN ORIGIN

J. Hauw, C. Négrier, N. Ifrah, 2006 .

[Portal vein thrombosis associated with protein S type 1 deficiency].

C. Négrier, N. Claudel, E. Vincent, 1992, Presse medicale.

Early septic shock induces loss of oxidative phosphorylation yield plasticity in liver mitochondria

J. Viale, D. Roussel, J. Morel, 2014, Journal of Physiology and Biochemistry.

PSY223 - QUALITATIVE RESEARCH IN HAEMOPHILIA A: EMICIZUMAB TRANSFORMS LIFESTYLE OF PATIENTS WITH INHIBITOR

C. Rothschild, C. Négrier, B. Arnould, 2018, Value in Health.

Reccurrent F8 Intronic Deletion Found in Mild Hemophilia A Causes Alu Exonization.

D. Bozon, A. Lienhart, C. Négrier, 2018, American journal of human genetics.

The Three In-frame ATG, Clustered in the Translation Initiation Sequence of Human Factor IX Gene, Are Required for an Optimal Protein Production

C. Négrier, M. Maurice, N. Enjolras, 1999, Thrombosis and Haemostasis.

Blood Coagulation, Fibrinolysis and Cellular Haemostasis Functional mapping of the A2 domain from human factor VIII

J. Pellequer, C. Négrier, M. Delcourt, 2022 .

Clinical and biological features of 3 cases of hypofibrinogenemia associated with three different mutations(γAla341Thr, Bβ Tyr326Cys and Aα Asp496Asn)

C. Négrier, M. Hanss, P. French, 2007, Thrombosis and Haemostasis.

Activated partial thromboplastin time waveform analysis: A new tool to detect infection?*

B. Allaouchiche, B. Floccard, C. Négrier, 2006, Critical care medicine.

Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.

C. Hermans, E. Santagostino, C. Kessler, 2019 .

Adaptability of protein A-immunoadsorption allows temporary reduction of anti-VIII antibodies and realisation of high-risk haemorrhagic surgery.

A. Lienhart, S. Meunier, C. Négrier, 2007, Transfusion and Apheresis Science.

FEIBA: looking toward the future

C. Négrier, E. Gomperts, 2006 .

Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.

D. S. Houston, M. Morfini, M. Torchet, 2001, Seminars in hematology.

Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study

C. Négrier, Y. Dargaud, J. Bordet, 2008, Journal of thrombosis and haemostasis : JTH.

Spectrum of the Mutations in Bernard–Soulier Syndrome

A. Pastore, P. Noris, R. Favier, 2014, Human mutation.

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults

V. Blanchette, C. Négrier, S. Lethagen, 2023, Research and practice in thrombosis and haemostasis.

Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation.

C. Négrier, Y. Dargaud, T. Lindhout, 2015, Blood.

Use of prior manufacturer specifications with Bayesian logic eludes preliminary phase issues in quality control: an example in a hemostasis laboratory.

Panagiotis Tsiamyrtzis, Frédéric Sobas, Claude Négrier, 2015, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

New approaches to using FEIBA in the treatment of inhibitor patients.

C. Leissinger, C. Négrier, N. Key, 2006, Seminars in thrombosis and hemostasis.